Market Overview

UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, Platform

Share:
Related CPHD
Novartis, Verastem & Cepheid Making Biotech Headlines On Friday
Benzinga's Top Upgrades

Bank of America initiated coverage on Cepheid (NASDAQ: CPHD) with a Buy rating and a $40 price objective.

Bank of America noted, "With one of the largest available test menus and more on the way, CPHD's prospects for increasing its installed base and reagent pull-through is positive, as it will become increasingly difficult for customers to justify supporting multiple platforms that run a limited number of tests. As more labs convert to MDx testing, we see CPHD as well positioned to grow. Moreover, our checks suggest that CPHD should see some success as it engages the MDx heavyweights in more established segments of the market (eg, CT/NG)."

Cepheid closed at $32.63 on Friday.

Latest Ratings for CPHD

DateFirmActionFromTo
Dec 2014Bank of AmericaUpgradesNeutralBuy
Dec 2014CitigroupMaintainsBuy
Dec 2014OppenheimerMaintainsOutperform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (CPHD)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content